DRG Epidemiology’s coverage of Vitiligo comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of Vitiligo for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.
DRG Epidemiology’s Vitiligo forecast will answer the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with Vitiligo?
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of Vitiligo?
- Of all people with Vitiligo, how many in each country have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Vitiligo over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following Vitiligo populations:
- Diagnosed prevalent cases
- … and more (details available on request).
Note: Coverage may vary by country.
- Epidemiology Dashboard
- Vitiligo Epidemiology Dashboard
Author(s): Sandeep Mahapatra, BDS, MPH
Sandeep is a dental graduate with a Master’s in Public Health with a specialization in Epidemiology and has been associated with DRG since June 2018. He works with a global team of epidemiologists in performing fully documented systematic reviews of published and grey literature on epidemiology of diseases and their risk factors. He also conducts analysis on descriptive epidemiology of major indications in mature and developing markets. Additionally, he supports the operational and strategic management of the team and wider business unit through collation of data from various sources. Prior to joining DRG he had over 5 years of experience working with state and central government of India to plan, design and conduct large scale research and implementation projects on non-communicable diseases, tobacco cessation and childhood nutrition.